Rosuvastatin
Mostrando 1-12 de 26 artigos, teses e dissertações.
-
1. Cardioprotection of Rosuvastatin Pre-conditioning on Myocardial Ischemia / Reperfusion Injury in a Rat Model
Abstract This study aimed to investigate the cardioprotection of rosuvastatin pre-conditioning (R-Pre) in a rat model of myocardial ischemia / reperfusion (I/R). Male SD rats were assigned into three groups: sham group, I/R group and R-Pre group. Rats in I/R group and R-Pre group received ischemia for 30 min and reperfusion for 2 h. In R-Pre group, rats rec
Braz. arch. biol. technol.. Publicado em: 25/11/2019
-
2. Circulating microparticles and central blood pressure according to antihypertensive strategy
OBJECTIVES: This prospective, randomized, open-label study aimed to compare the effects of antihypertensive treatment based on amlodipine or hydrochlorothiazide on the circulating microparticles and central blood pressure values of hypertensive patients. METHODS: The effects of treatments on circulating microparticles were assessed during monotherapy and a
Clinics. Publicado em: 11/11/2019
-
3. Evaluating the discriminatory power of a dissolution assay for rosuvastatin calcium capsules: Solid-state properties and dissolution media
We propose to evaluate the dissolution properties of rosuvastatin calcium (ROSC) capsules in different media to characterize the discriminatory power of the assay method. Dissolution assays were performed in media with different pH, and including the surfactant sodium dodecyl sulfate (SDS). Several immediate-release formulations were manufactured using the c
Braz. J. Pharm. Sci.. Publicado em: 23/09/2019
-
4. Spectrophotometric determination of rosuvastatin in pharmaceutical formulations using quinalizarin
ABSTRACT This work presents the development of a methodology based on the formation of a charge transfer complex between quinalizarin and rosuvastatin, allowing for the spectrophotometric determination of rosuvastatin at 579 nm. The factors involved in the sensitivity of the technique were studied (nature and proportion of the solvent, reaction time, pH of a
Braz. J. Pharm. Sci.. Publicado em: 31/07/2017
-
5. Simultaneous estimation of rosuvastatin and amlodipine in pharmaceutical formulations using stability indicating HPLC method
Utilizou-se abordagem de viabilidade custo-efetividade e isocrática, baseada em CLAE, empregando coluna C-18 (250 mm x 4,6 mm, 5 µm) para separar e avaliar os fármacos, rosuvastatina, anlodipino e seus produtos de degradação induzida por estresse, simultaneamente, em formulações farmacêuticas. Focada nos parâmetros das diretrizes da ICH, a separaç�
Braz. J. Pharm. Sci.. Publicado em: 2014-09
-
6. Differences in synthesis and absorption of cholesterol of two effective lipid-lowering therapies
Effective statin therapy is associated with a marked reduction of cardiovascular events. However, the explanation for full benefits obtained for LDL cholesterol targets by combined lipid-lowering therapy is controversial. Our study compared the effects of two equally effective lipid-lowering strategies on markers of cholesterol synthesis and absorption. A pr
Braz J Med Biol Res. Publicado em: 2012-11
-
7. Efeitos da rosuvastatina e da atividade física de baixa intensidade na morfologia renal de ratos normotensos e espontaneamente hipertensos (SHR) / Effects of the rosuvastatin and low intensity physical activity on the morphology of kidney from normotensive and spontaneously hypertensive rats (SHR)
Desordens do sistema renal podem ser as causas da hipertensão arterial, a qual pode, por sua vez, causar doenças renais. A pressão sanguínea elevada é muito comum também nas doenças crônicas dos rins, e é, além disso, um conhecido fator de risco para uma mais rápida progressão da falha renal. A incidência de doenças renais crônicas está aumen
IBICT - Instituto Brasileiro de Informação em Ciência e Tecnologia. Publicado em: 30/09/2011
-
8. Efeitos benéficos da rosuvastatina na estrutura renal de ratos espontaneamente hipertensos (SHR) / Rosuvastatin beneficially alters the glomerular structure of kidneys from spontaneously hypertensive rats (SHRs)
A incidência de doenças renais crônicas está aumentando no mundo, e há uma grande necessidade de identificar as terapias capazes de deter ou reduzir a progressão da doença. Há crescente evidência clínica e experimental de que as estatinas poderiam desempenhar um papel terapêutico. Recentes estudos clínicos e experimentais têm mostrado que as est
IBICT - Instituto Brasileiro de Informação em Ciência e Tecnologia. Publicado em: 26/04/2011
-
9. Rosuvastatin prevents myocardial necrosis in an experimental model of acute myocardial infarction
Dyslipidemia is related to the progression of atherosclerosis and is an important risk factor for acute coronary syndromes. Our objective was to determine the effect of rosuvastatin on myocardial necrosis in an experimental model of acute myocardial infarction (AMI). Male Wistar rats (8-10 weeks old, 250-350 g) were subjected to definitive occlusion of the l
Brazilian Journal of Medical and Biological Research. Publicado em: 2011-05
-
10. The methyl ester of rosuvastatin elicited an endothelium-independent and 3-hydroxy-3-methylglutaryl coenzyme A reductase-independent relaxant effect in rat aorta
The relaxant effect of the methyl ester of rosuvastatin was evaluated on aortic rings from male Wistar rats (250-300 g, 6 rats for each experimental group) with and without endothelium precontracted with 1.0 µM phenylephrine. The methyl ester presented a slightly greater potency than rosuvastatin in relaxing aortic rings, with log IC50 values of -6.88 and -
Brazilian Journal of Medical and Biological Research. Publicado em: 2011-05
-
11. Rosuvastatin prevents proteinuria and renal inflammation in nitric oxide-deficient rats
OBJECTIVE: The aim of the present study was to assess the effects of rosuvastatin on renal injury and inflammation in a model of nitric oxide deficiency. METHODS: Male Wistar rats were randomly divided into four groups (n = 10/group) and treated for 28 days with saline (CTRL); 30 mg/kg/day L-NAME (L-name); L-NAME and 20 mg/kg/day rosuvastatin (L-name+ROS-20)
Clinics. Publicado em: 2011
-
12. Degradação fotocatalítica de rosuvastatina em solução aquosa empregando ZnO em suspensão : cinética, subprodutos e toxicidade
The photocatalytic degradation of Rosuvastatin, a drug used to reduce blood cholesterol levels, employing ZnO as catalyst was studied in this work. The experiments were carried out in a UV irradiated batch reactor, equipped with temperature control. The effect of catalyst concentration, initial pH and initial Rosuvastatin concentration were evaluated. Photol
IBICT - Instituto Brasileiro de Informação em Ciência e Tecnologia. Publicado em: 2011